Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Drug: FSH

PreclinicalSmall molecule

EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Drug: FSH is one of 15 small molecule programs targeting Ovarian. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

14

Competitors

Pipeline

Status by Indication[3][1]

Indication

OvarianCompleted

OvarianPreclinical

Completed

Competition

Competitive Landscape

15 competitors in Ovarian

#DrugCompanyPhaseTrials

Avastin

Taxol

Eloxatin

Paraplatin

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Rapamycin

MMaastricht Radiation Oncology

Lynparza

Clomid

Human Chorionic Gonadotropin

MEDI4736

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ovarian1 trial

Feasibility Study for Development of an Early Test for Ovarian Failure

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00006156·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: FSH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug: FSH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug: FSH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Related News